Patents by Inventor Peter C. Brooks

Peter C. Brooks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENHANCING THE THERAPEUTIC ACTIVITY OF IMMUNE CHECKPOINT INHIBITOR
    Publication number: 20210155696
    Abstract: The present invention provides antagonists and methods of use thereof in the treatment of cancer and abnormal immune suppression diseases.
    Type: Application
    Filed: December 9, 2020
    Publication date: May 27, 2021
    Inventors: Peter C. Brooks, Jennifer M. Caron, Liangru Contois
  • ENHANCING THE THERAPEUTIC ACTIVITY OF AN IMMUNE CHECKPOINT INHIBITOR
    Publication number: 20210100901
    Abstract: The present invention provides antagonists and methods of use thereof in the treatment of cancer and abnormal immune suppression diseases.
    Type: Application
    Filed: December 3, 2020
    Publication date: April 8, 2021
    Inventors: Peter C. Brooks, Jennifer M. Caron, Liangru Contois
  • Enhancing the therapeutic activity of immune checkpoint inhibitor
    Patent number: 10906977
    Abstract: The present invention provides antagonists and methods of use thereof in the treatment of cancer and abnormal immune suppression diseases.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: February 2, 2021
    Assignee: Maine Medical Center Research Institute
    Inventors: Peter C. Brooks, Jennifer M. Caron, Liangru Contois
  • Enhancing the therapeutic activity of an immune checkpoint inhibitor
    Patent number: 10881732
    Abstract: The present invention provides antagonists and methods of use thereof in the treatment of cancer and abnormal immune suppression diseases.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: January 5, 2021
    Assignee: Maine Medical Center Research Institute
    Inventors: Peter C. Brooks, Jennifer M. Caron, Liangru Contois
  • Compositions and methods for treating inflammation and fibrosis
    Patent number: 9890208
    Abstract: The present invention features compositions featuring agents that bind to denatured collagen and methods of using such agents to treat or prevent fibrosis or inflammation in a subject.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: February 13, 2018
    Assignee: Maine Medical Center
    Inventors: Peter C. Brooks, Leif Oxburgh, Jennifer M. Caron
  • ENHANCING THE THERAPEUTIC ACTIVITY OF IMMUNE CHECKPOINT INHIBITOR
    Publication number: 20170240638
    Abstract: The present invention provides antagonists and methods of use thereof in the treatment of cancer and abnormal immune suppression diseases.
    Type: Application
    Filed: February 17, 2017
    Publication date: August 24, 2017
    Inventors: Peter C. Brooks, Jennifer M. Caron
  • ENHANCING THE THERAPEUTIC ACTIVITY OF AN IMMUNE CHECKPOINT INHIBITOR
    Publication number: 20170065716
    Abstract: The present invention provides antagonists and methods of use thereof in the treatment of cancer and abnormal immune suppression diseases.
    Type: Application
    Filed: June 1, 2016
    Publication date: March 9, 2017
    Inventors: Peter C. Brooks, Jennifer M. Caron, Liangru Contois
  • Treatment of cancer using benzoic acid derivatives
    Patent number: 9018259
    Abstract: The present invention provides a method of treating cancer using benzoic acid derivatives, alone or in combination with standard treatments such as chemotherapy and radiotherapy. Also provided are methods of screening for benzoic derivatives based on their ability to inhibit the enzyme tyrosinase or to bind to and activate PXR/SXR xenobiotic receptors.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: April 28, 2015
    Assignee: New York University
    Inventors: Peter C. Brooks, Danielle Morais, Leonard Liebes, Dorothy Rodriguez
  • COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION AND FIBROSIS
    Publication number: 20150010552
    Abstract: The present invention features compositions featuring agents that bind to denatured collagen and methods of using such agents to treat or prevent fibrosis or inflammation in a subject.
    Type: Application
    Filed: September 17, 2014
    Publication date: January 8, 2015
    Inventors: Peter C. Brooks, Leif Oxburgh, Jennifer M. Caron
  • Treatment of cancer using the sodium salt of a benzoic acid derivative
    Patent number: 8710099
    Abstract: The present invention provides a method of treating cancer using the sodium salt of a benzoic acid derivative, alone or in combination with standard treatments such as chemotherapy and radiotherapy.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: April 29, 2014
    Assignees: New York University, Maine Medical Center
    Inventors: Peter C. Brooks, James Canary, Leonard Liebes
  • TREATMENT OF CANCER USING BENZOIC ACID DERIVATIVES
    Publication number: 20120329861
    Abstract: The present invention provides a method of treating cancer using benzoic acid derivatives, alone or in combination with standard treatments such as chemotherapy and radiotherapy. Also provided are methods of screening for benzoic derivatives based on their ability to inhibit the enzyme tyrosinase or to bind to and activate PXR/SXR xenobiotic receptors.
    Type: Application
    Filed: May 14, 2012
    Publication date: December 27, 2012
    Applicant: NEW YORK UNIVERSITY
    Inventors: Peter C. Brooks, Danielle Morais, Leonard Liebes, Dorothy Rodriguez
  • COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION AND FIBROSIS
    Publication number: 20120237504
    Abstract: The present invention features compositions featuring agents that bind to denatured collagen and methods of using such agents to treat or prevent fibrosis or inflammation in a subject.
    Type: Application
    Filed: October 14, 2010
    Publication date: September 20, 2012
    Applicant: MAINE MEDICAL CENTER
    Inventors: Peter C. Brooks, Leif Oxburg, Jennifer M. Roth
  • TREATMENT OF CANCER USING THE SODIUM SALT OF A BENZOIC ACID DERIVATIVE
    Publication number: 20120203051
    Abstract: The present invention provides a method of treating cancer using the sodium salt of a benzoic acid derivative, alone or in combination with standard treatments such as chemotherapy and radiotherapy.
    Type: Application
    Filed: September 10, 2010
    Publication date: August 9, 2012
    Applicants: MAINE MEDICAL CENTER, NEW YORK UNIVERSITY
    Inventors: Peter C. Brooks, James Canary, Leonard Liebes
  • Treatment of cancer using benzoic acid derivatives
    Patent number: 8198328
    Abstract: The present invention provides a method of treating cancer using benzoic acid derivatives, alone or in combination with standard treatments such as chemotherapy and radiotherapy. Also provided are methods of screening for benzoic derivatives based on their ability to inhibit the enzyme tyrosinase or to bind to and activate PXR/SXR xenobiotic receptors.
    Type: Grant
    Filed: January 19, 2005
    Date of Patent: June 12, 2012
    Assignee: New York University
    Inventors: Peter C. Brooks, Danielle Morais, Leonard Liebes, Dorothy Rodriguez
  • CLK-peptide and SLK-peptide
    Patent number: 8133471
    Abstract: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen type-IV with substantially greater affinity than to the native triple helical form of collagen type-IV. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo. The invention further describes methods for treating tumors using said antagonists in combination with radiation therapy and therapies comprising the antagonists and radiation treatment.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: March 13, 2012
    Assignee: New York University
    Inventors: Peter C. Brooks, Jennifer Roth, Abebe Akalu
  • Antagonists and methods for inhibiting angiogenesis
    Patent number: 8025883
    Abstract: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen but not to native triple helical forms of the collagen. Antagonists of the invention can target, for example, denatured collagens type-I, type-II, type-III, type-IV, type-V and combinations thereof. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis is normal or diseased tissues both in vivo and ex vivo. Antagonists include monoclonal antibodies referred to as HUI77, HUIV26, and XL313.
    Type: Grant
    Filed: September 15, 2005
    Date of Patent: September 27, 2011
    Assignee: University of Southern California
    Inventors: Peter C. Brooks, Jingsong Xu, Eric Petitclerc
  • INHIBITION OF MELANOGENESIS AND MELANOMA METASTASIS WITH P-AMINO BENZOIC ACID (PABA)
    Publication number: 20100323002
    Abstract: The present invention relates to the inhibition of melanogenesis with para-aminobenzoic acid (PABA) and its use in treating melanotic cancer.
    Type: Application
    Filed: February 5, 2010
    Publication date: December 23, 2010
    Applicant: NEW YORK UNIVERSITY
    Inventors: Peter C. Brooks, Danielle Morais, Dorothy Rodriguez
  • CLK-PEPTIDE AND SLK-PEPTIDE
    Publication number: 20100226852
    Abstract: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen type-IV with substantially greater affinity than to the native triple helical form of collagen type-IV. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo. The invention further describes methods for treating tumors using said antagonists in combination with radiation therapy and therapies comprising the antagonists and radiation treatment.
    Type: Application
    Filed: December 21, 2009
    Publication date: September 9, 2010
    Applicant: NEW YORK UNIVERSITY
    Inventors: Peter C. Brooks, Jennifer Roth, Abebe Akalu
  • Methods for treating non-melanoma cancers with PABA
    Patent number: 7705049
    Abstract: The present invention relates to a method for treating non-melanotic cancers by administration of PABA. The present invention also relates to the potentiation of standard cancer treatment of radiation, radioimmunotherapy, and/or chemotherapy using PABA.
    Type: Grant
    Filed: January 20, 2005
    Date of Patent: April 27, 2010
    Assignee: New York University
    Inventors: Peter C. Brooks, Leonard Liebes, Elissa Kramer, Bruce Ng, Danielle Morais
  • Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA)
    Patent number: 7691905
    Abstract: The present invention relates to the inhibition of melanogenesis with para-aminobenzoic acid (PABA) and its use in treating melanotic cancer.
    Type: Grant
    Filed: December 23, 2003
    Date of Patent: April 6, 2010
    Assignee: New York University
    Inventors: Peter C. Brooks, Danielle Morais, Dorothy Rodriguez